PTP.XETRA PENTIXAPHARM HOLDING N AG

Healthcare Biotechnology XETRA Stock Exchange
2.01 EUR
Close of Nov 6, 2026
1.30 3.70
Market cap
EUR 72.0M
P/E
-
P/B
2.19x
ROE
-48.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PTP.XETRA undervalued?

Graham number

The Graham number of PENTIXAPHARM HOLDING N AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PENTIXAPHARM HOLDING N AG fundamental analysis

No fundamental analysis for PENTIXAPHARM HOLDING N AG yet.

PENTIXAPHARM HOLDING N AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PENTIXAPHARM HOLDING N AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based …

Full company profile